Capricor Therapeutics (STU:4LN2) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Capricor Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was €0.00 Mil. Capricor Therapeutics's average total debt for the quarter that ended in Mar. 2025 was €1.27 Mil. Therefore, Capricor Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 0.00%.

Capricor Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Capricor Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Effective Interest Rate on Debt % Chart

Capricor Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

Capricor Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Capricor Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Capricor Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Effective Interest Rate on Debt % falls into.

Save Embed

;

Save Embed

;

Capricor Therapeutics Effective Interest Rate on Debt % Calculation

Capricor Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2023 )	+	Total Debt (A: Dec. 2024 ))	/ count )
=	-1 * 0	/	( (2.051	+	1.385)	/ 2 )
=	-1 * 0	/	1.718
=	0.00 %

where

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.364	+	0.687
=	2.051

	Total Debt (A: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.588	+	0.797
=	1.385

Capricor Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2024 )	+	Total Debt (Q: Mar. 2025 ))	/ count )
=	-1 * 0	/	( (1.385	+	1.155)	/ 2 )
=	-1 * 0	/	1.27
=	0.00 %

where

	Total Debt (Q: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.588	+	0.797
=	1.385

	Total Debt (Q: Mar. 2025 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.376	+	0.779
=	1.155

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Capricor Therapeutics (STU:4LN2) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Capricor Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

CAPR:USA 4LN2:Germany

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Headlines

No Headlines